Member Info for Richob

Apparently I am. Sarcoma is classed as solid.

Apologies.

Onwards Avacta.

I think what is perhaps of more interest is that, as I understand the trial, it is for metastolic solid tumours but orphan drug status has been granted for soft tissue sarcoma.

Am I somehow getting this wrong?

Onwards Avacta.

I'm sure Neil Bell is on the case in any event.

Onwards Avacta.

Agreed, jive but AVA3996 would not be AVA6000?

https://www.americangene.com/blog/benefits-of-fda-orphan-drug-designation-what-you-need-to-know/

Onwards Avacta.

Don't see why not, icecool. Looks like there are a lot of these "smaller number" diseases:

https://www.orphandiseasecenter.med.upenn.edu/

Onwards Avacta.

Let's not forget Affyxell MrRipley:

https://avacta.com/affyxell-expands-its-strategic-partnership-with-genscript-probio/

One of a number we could mention.

Onwards Avacta.

ODX also there. Great spot, gadgie

Onwards Avacta.

The inventor of auto correct has just passed away.

His funeral will be held tomato.

Went to see my therapist as I couldn't get the theme tune to Grease out of my mind.

He said tell me more.

... why would Genscript bio, a £4bn company (if my HK$ to £ is correct) want to tie up with Affyxell?

https://avacta.com/affyxell-expands-its-strategic-partnership-with-genscript-probio/

It has been four months since the CEO of Genscript said "soon".

Onwards Avacta.

My wife said that I never buy her flowers.

I said to be honest love I didn't know you sold them.

Have another Rum Diplomatico could you all?

Onwards Avacta.

Might I suggest a Rum Diplomatico?

Good for the discussion I have heard.

Onwards Avacta.

Which RNS Mr A?

Thanks.

Richob.

... but it looks like AS has a runner in the 150 at Hexham.

Genscript Bio clearly believe this will work.

Onwards Avacta.

Looks like more people like his post than yours one knows.

Are you for Avacta or not?

Don't care really but of then latter then why waste your time and ours?

Onwards Avacta.

He can't read.

Income has increased.

There is cash in the bank.

Progress on various fronts (AVA6000 being one).

This is p**s poor obviously.

Bring it on here, son, we can have a reasoned debate. Lol.

Onwards Avacta.

... that the post reporting period highlights warrant attention in addition to the more positive income and cash position that has been achieved.

1) ALS-6000-101 study advanced to dosing the fourth dose cohort of patients following a positive review in August of the safety and tolerability data from the dosing of the third cohort.

Yes, we obviously knew this but it is good to see safety mentioned yet again.

2) The US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to AVA6000 for treatment of soft tissue sarcoma.

Again we knew this but it is clearly a reflection of data in the current trial. Poor data and this would not have been granted.

3) AffyXell successfully completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider pre-clinical pipeline of cell therapies.

For me, this is a massive springboard given who we are collaborating with.

Diagnostics - Building a portfolio of products in an ISO13485 accredited in-vitro diagnostic products business.

Not unless they know the products work I would have thought.

In summary, for me anyway, the update was at least good and actually better than good given the scare mongering we saw ahead of it.

The next six monthly update will doubtless have the success of AVA6000 in it, way likely a mention of AVA3996 in it and who knows what from Diagnostics, Affyxell, LG Chem, Point Biopharma and others.

Not sure what anybody else might be looking for in an AIM share.

Onwards Avacta.

Looks to be moving along very well, gmcc.

Onwards Avacta.